FIELD: chemistry of organic compounds; pharmacology and medicine.
SUBSTANCE: invention concerns new peptides. The claimed peptides are characterized by high antibacterial activity with a broad spectrum of action and are promising for use in the treatment of infectious diseases in a subject caused by a bacterial infection, including diseases caused by antibiotic-resistant (including multi-resistant) bacterial strains.
EFFECT: compounds of the invention are characterized by the ability to inhibit pathogen strains, including pathogen strains that are not sensitive to commonly used medicinal products, in particular carbapenem-resistant bacterial isolates.
14 cl, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE WITH ANTIBACTERIAL ACTIVITY | 2024 |
|
RU2825930C1 |
| MODIFIED ENDOLYSIN AND ANTIBACTERIAL COMPOSITIONS BASED THEREON FOR TREATING INFECTIONS CAUSED BY ACINETOBACTER BAUMANNII, PSEUDOMONAS AERUGINOSA, KLEBSIELLA PNEUMONIAE, ESCHERICHIA COLI BACTERIA | 2023 |
|
RU2813626C1 |
| METHOD FOR THE TREATMENT AND PREVENTION OF RECURRENCE OF NOSOCOMIAL PNEUMONIA | 2021 |
|
RU2794585C2 |
| USE OF 6-FLUORO-3-TRIAZENONE INDOLES FOR THERAPY OF INFECTIONS CAUSED BY MRSA | 2019 |
|
RU2712265C1 |
| POLYPEPTIDE WITH ANTIBACTERIAL ACTIVITY, COMPOSITION FOR THE PREVENTION OR TREATMENT OF SEPSIS WHICH INCLUDES IT, AND ANTIBACTERIAL COMPOSITION | 2020 |
|
RU2797347C2 |
| METHOD OF PRODUCING AMINO ACID SEQUENCES CODING NANOANTIBODIES NEUTRALIZING CLOSTRIDIOIDES DIFFICILE A TOXIN | 2023 |
|
RU2833930C1 |
| ANTIGENIC PEPTIDES FOR PREVENTION AND TREATMENT OF B-CELL HEMOBLASTOSIS | 2020 |
|
RU2833806C1 |
| METHOD FOR PREVENTION OF HEALTHCARE-ASSOCIATED INFECTIONS IN PATIENTS IN CHRONIC CRITICAL CONDITION | 2023 |
|
RU2818910C1 |
| PEPTIDES AND USE THEREOF | 2011 |
|
RU2590706C2 |
| MONOCLONAL ANTIBODIES SPECIFIC TO PROTEIN RUSTICYANIN, AND USE OF ANTIBODIES FOR DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS | 2024 |
|
RU2823344C1 |
